Breaking News
EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow
EnGeneIC has announced the successful dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital, Sydney. The trial (ENG19) is an essential next step in progressing EnGeneIC’s novel platform technology through the clinic and to market. It will assess the safety and efficacy of EGFR-targeted EDVTM (EnGeneIC Dream Vector) nanocells carrying the super-cytotoxic drug PNU-159682, together with EDVs loaded with an immune-stimulating adjuvant in patients with advanced solid tumours expressing Epidermal Growth Factor Receptor (EGFR).
EnGeneIC selects Global CDMO BioCina to Advance Their Groundbreaking Cancer Treatment
Adelaide, South Australia, September 25, 2024. BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells.
EngeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment
Sydney, Australia, June 06, 2024 (GLOBE NEWSWIRE) EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-In-Class targeted nanocell for cancer therapy has today announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). The partnerships will bring significant new funding to allow EnGeneIC to immediately progress its clinical trial programmes in Australia and the USA. Further, the agreements aim to accelerate the clinical development, manufacture and commercialisation of EnGeneIC’s proprietary technology, EnGeneIC Dream Vector (EDV™) for cancer treatment across asia
